<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Summary of clinical, laboratory, and radiographic findings and treatment of neonatal herpes simplex virus infection</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Summary of clinical, laboratory, and radiographic findings and treatment of neonatal herpes simplex virus infection</h1>
<div class="graphic"><div class="figure"><div class="ttl">Summary of clinical, laboratory, and radiographic findings and treatment of neonatal herpes simplex virus infection</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="7%"></colgroup><colgroup width="19%"></colgroup><colgroup span="4" width="7%"></colgroup><colgroup span="2" width="19%"></colgroup> <tbody> <tr> <td class="subtitle1" rowspan="2"> </td> <td class="subtitle1" rowspan="2">Proportion of cases</td> <td class="subtitle1" rowspan="2">Clinical manifestations</td> <td class="subtitle1" colspan="4">Diagnostic testing for HSV*</td> <td class="subtitle1" rowspan="2">Other laboratory and radiographic findings</td> <td class="subtitle1" rowspan="2">Recommended treatment</td> </tr> <tr> <td class="subtitle2">Viral culture or HSV PCR of surface <span class="nowrap_whitespace">swabs<sup>¶</sup></span></td> <td class="subtitle2">Viral culture or HSV PCR of skin lesion <span class="nowrap_whitespace">scrapings<sup>Δ</sup></span></td> <td class="subtitle2">Blood or plasma HSV PCR</td> <td class="subtitle2">CSF HSV PCR</td> </tr> <tr> <td><strong>SEM disease</strong></td> <td>35 to 45%</td> <td> <ul> <li>Characteristic vesicular lesions</li> <li>Conjunctivitis, excessive tearing</li> <li>Ulcerative lesions of the mouth, palate, and tongue</li> </ul> </td> <td>Positive in &gt;90%</td> <td>Positive in &gt;90%</td> <td>Positive in approximately 75%</td> <td>Negative</td> <td> <ul> <li>Other laboratory and radiographic studies are typically normal</li> </ul> </td> <td> <p>Initial treatment: Acyclovir 60 mg/kg per day intravenously divided every 8 hours for <span class="nowrap_whitespace">14 days<sup>◊</sup></span></p> <p>Followed by:</p> <p>Oral suppressive therapy: Acyclovir 300 mg/m<sup>2</sup> per dose orally 3 times per day for <span class="nowrap_whitespace">6 months<sup>◊</sup></span></p> In addition, for ocular involvement: <ul class="decimal_heading"> <li>Topical ophthalmic solution (eg, 1% trifluridine, 0.1% idoxuridine <span class="nowrap_whitespace">[iododeoxyuridine]<sup>§</sup>,</span> or 0.15% ganciclovir)</li> <li>Referral to an ophthalmologist</li> <li>Longer duration of oral suppressive therapy may be warranted</li> </ul> </td> </tr> <tr> <td><strong>CNS disease</strong></td> <td>30 to 35%</td> <td> <ul> <li>Seizures</li> <li>Lethargy</li> <li>Irritability</li> <li>Tremors</li> <li>Poor feeding</li> <li>Apnea</li> <li>Skin lesions are present in 60 to 70%</li> </ul> </td> <td>Positive in &gt;90%</td> <td>Positive in &gt;90% if lesions are present; however, skin lesions are often not present at the onset of disease</td> <td>Positive in approximately 65%</td> <td>Positive in 75 to 100%</td> <td> <ul> <li>CSF analysis classically shows a mononuclear cell pleocytosis, normal or moderately low glucose concentration, and mildly elevated protein</li> <li>EEG may show focal or multifocal LPDs</li> <li>Neuroimaging studies may show parenchymal brain edema or attenuation, hemorrhage, or destructive lesions involving the temporal, frontal, parietal, or brainstem regions of the brain</li> </ul> </td> <td> <p>Initial treatment: Acyclovir 60 mg/kg per day intravenously divided every 8 hours for a minimum of <span class="nowrap_whitespace">21 days<sup>◊</sup></span></p> <p>Followed by:</p> Oral suppressive therapy: Acyclovir 300 mg/m<sup>2</sup> per dose orally 3 times per day for <span class="nowrap_whitespace">6 months<sup>◊</sup></span></td> </tr> <tr> <td><strong>Disseminated disease</strong></td> <td>25 to 30%</td> <td> <ul> <li>Sepsis syndrome</li> <li>Fever or hypothermia</li> <li>Hepatitis</li> <li>Respiratory distress</li> <li>DIC</li> <li>Skin lesions are present in 60 to 80%</li> <li>CNS involvement occurs in 60 to 75%</li> </ul> </td> <td>Positive in &gt;90%</td> <td>Positive in &gt;90% if lesions are present; however, skin lesions are often not present at the onset of disease</td> <td>Positive in 100%</td> <td>Positive in &gt;90%</td> <td> <ul> <li>Elevated liver transaminases</li> <li>Thrombocytopenia</li> <li>Abnormal CSF, EEG, and neuroimaging studies, as above</li> </ul> </td> <td> <p>Initial treatment: Acyclovir 60 mg/kg per day intravenously divided every 8 hours for a minimum of <span class="nowrap_whitespace">21 days<sup>◊</sup></span></p> <p>Followed by:</p> Oral suppressive therapy: Acyclovir 300 mg/m<sup>2</sup> per dose orally 3 times per day for <span class="nowrap_whitespace">6 months<sup>◊</sup></span></td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>HSV: herpes simplex virus; PCR: polymerase chain reaction; CSF: cerebrospinal fluid; SEM: skin, eyes, mouth; CNS: central nervous system; EEG: electroencephalogram; LPD: lateralized periodic discharges (previously known as PLEDs [periodic lateralized epileptiform discharges]); DIC: disseminated intravascular coagulopathy; DFA: direct immunofluorescence assay; IV: intravenous; BSA: body surface area.</p>
<p>* All of these diagnostic tests should be performed in any neonate with suspected HSV infection.</p>
<p>¶ Surface swabs are performed on specimens collected from the conjunctivae, mouth, nasopharynx, and rectum. Some experts suggest these be obtained with a single swab, starting with eyes and ending with the rectum, and placed in 1 viral transport media tube. Alternatively, they may be collected with multiple swabs.</p>
<p>Δ DFA permits rapid detection of HSV antigens in skin lesion scrapings; however, DFA is not as sensitive as culture or PCR and therefore viral culture and/or PCR should also be performed.</p>
<p>◊ The dose of acyclovir must be adjusted for neonates with renal impairment and/or weight &lt;1 kg. Refer to Lexicomp for additional dosing information. If IV acyclovir is not available, ganciclovir is an alternative. Refer to the UpToDate's topic on management of neonatal HSV infection for additional information. Oral acyclovir dosing is based on BSA, which is calculated as follows: square root <span class="nowrap_whitespace">(height [cm] × weight [kg]/3600).</span> The oral suppressive acyclovir dose should be adjusted each month to account for growth.</p>
§ Idoxuridine (iododeoxyuridine) is not available in the United States.</div><div id="graphicVersion">Graphic 106132 Version 5.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
